Mental Health Drugs Face Contracting Challenges From Part D Formulary Proposal
CMS estimates that removing antidepressants, antipsychotics and immunosuppressants from “protected class” status in Medicare Part D could save $720 million between 2016 and 2019.
You may also be interested in...
In a letter to Congress, CMS Administrator Tavenner says that due to strong opposition from members of Congress and stakeholders, it will not finalize several controversial proposals in its recent draft rule for Medicare Part D, including removal of special formulary protection for three drug classes.
The Energy & Commerce Health Subcommittee plans a Feb. 26 hearing to air members’ opposition to CMS’ proposed rule on Medicare Part D, and Republicans warn that failure to “reject” the proposed rule “will force Congress to evaluate all legislative options necessary to ensure seniors are protected.”
PhRMA CEO John Castellani explains in an interview why Medicare Part D stakeholders are united in the concern that the sweeping changes proposed by CMS will “harm patients, limit choice and ultimately will raise costs in a program that by any measure is working well.”